Abstract

Sickle cell anemia (SCA) is a genetic blood disorder that is particularly lethal in early childhood. Universal newborn screening programs and subsequent early treatment are known to drastically reduce under-five SCA mortality. However, in resource-limited settings, cost and infrastructure constraints limit the effectiveness of laboratory-based SCA screening programs. To address this limitation our laboratory previously developed a low-cost, equipment-free, point-of-care, paper-based SCA test. Here, we improved the stability and performance of the test by replacing sodium hydrosulfite (HS), a key reducing agent in the hemoglobin solubility buffer which is not stable in aqueous solutions, with sodium metabisulfite (MS). The MS formulation of the test was compared to the HS formulation in a laboratory setting by inexperienced users (n = 3), to determine visual limit of detection (LOD), readout time, diagnostic accuracy, intra- and inter-observer agreement, and shelf life. The MS test was found to have a 10% sickle hemoglobin LOD, 21-min readout time, 97.3% sensitivity and 99.5% specificity for SCA, almost perfect intra- and inter-observer agreement, at least 24 weeks of shelf stability at room temperature, and could be packaged into a self-contained, distributable test kits comprised of off-the-shelf disposable components and food-grade reagents with a total cost of only $0.21 (USD).

Highlights

  • Sickle cell disease (SCD) refers to a group of common recessively inherited hemoglobin disorders associated with significant lifelong morbidities and premature mortality

  • The limit of detection (LOD) for this test is defined as the lowest percentage of HbS that will produce a blood stain on paper which is visually distinguishable from characteristic blood stains for samples without HbS (0%)

  • Universal screening for Sickle cell anemia (SCA) using conventional, laboratory-based methods (e.g., isoelectric focusing electrophoresis (IEF), high-performance liquid chromatography (HPLC)) is currently unfeasible in many resource-limited settings because of the prohibitively high cost and lack of access to the technical infrastructure required to support such testing

Read more

Summary

Introduction

Sickle cell disease (SCD) refers to a group of common recessively inherited hemoglobin disorders associated with significant lifelong morbidities and premature mortality. SCD results from the inheritance of a mutated allele coding for the β-globin subunit of hemoglobin along with another mutated allele coding for the same or another aberrant form of hemoglobin [1,2]. This mutated β-globin allele results in the production of sickle hemoglobin (HbS), a form of hemoglobin (Hb) that polymerizes when deoxygenated, unlike normal adult hemoglobin (HbA). Sickle RBCs are markedly less deformable and more fragile than normal, healthy RBCs, which causes them to occlude blood vessels, cause chronic ischemia-reperfusion injury, and lyse frequently, resulting in severe anemia, chronic painful episodes, and predisposition to infection [3,4].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call